Outcomes Of The Spanish Cohort Of Early Access To Pertuzumab And Trastuzumab Emtansine (KNOWHER)
Use Of Pertuzumab And Trastuzumab Emtansine In Adult Patients With Her2-Positive Metastatic Or Locally Recurrent Unresectable Breast Cancer
研究概览
地位
条件
详细说明
This is a retrospective, non-interventional, non-comparative, observational cohort study / registry in the Spain. The study design will reflect real-life clinical management of patients with HER2-positive MBC. Type and frequency of actual patient visits and all evaluations will be done as for routine clinical practice.
The analysis of the efficacy and safety results obtained in patients receiving pertuzumab or TDM1 in those early access systems is of utmost importance. These real-world patients with advanced breast cancer may have different characteristics than those enrolled in clinical trials and clinicians must often extrapolate into therapeutic decisions not fully supported by a robust evidence.
研究类型
注册 (实际的)
联系人和位置
学习地点
-
-
-
Madrid、西班牙、28222
- Puerta de Hierro University Hospital
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
取样方法
研究人群
描述
Inclusion Criteria:
- Adult patients (age ≥ 18 years at enrolment) with HER2-positive metastatic or locally recurrent unresectable breast cancer and who are treated with Trastuzumab emtansine (T-DM1) or Pertuzumab.
- Patients who initiate Trastuzumab emtansine (T-DM1) and Pertuzumab under Spanish compassionate use or early access program.
Exclusion Criteria:
- Given the characteristics of the study there are no exclusion criteria.
学习计划
研究是如何设计的?
设计细节
队列和干预
团体/队列 |
---|
Pertuzumab
Patients with HER2-positive metastatic or locally recurrent unresectable breast cancer and who are treated with Pertuzumab under Spanish compassionate use or early access program
|
Trastuzumab emtansine
Patients with HER2-positive metastatic or locally recurrent unresectable breast cancer and who are treated with Trastuzumab emtansine (T-DM1) under Spanish compassionate use or early access program
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
---|---|---|
Overall survival.
大体时间:Through study completion (from date of start of treatment until the date of death from any cause, assessed up to 48 months).
|
The time between the date of start of treatment and the date of death.
For subjects without documentation of death, OS will be censored on the last date the subject was known to be alive
|
Through study completion (from date of start of treatment until the date of death from any cause, assessed up to 48 months).
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
---|---|---|
Progression free survival.
大体时间:Through study completion (from date of start of treatment until the date of first documented progression assessed up to 48 months)
|
The time from start of treatment to the date of the first documented tumour progression as determined by the clinician (may be based on clinical examination or radiographic or laboratory features).
|
Through study completion (from date of start of treatment until the date of first documented progression assessed up to 48 months)
|
Best overall response rate
大体时间:Through study completion, an average of 4 year
|
Response rate is defined as the proportion of patients with complete response (CR) or partial response (PR) based on their best overall response as written in the medical record
|
Through study completion, an average of 4 year
|
Duration of response (DOR)
大体时间:Through study completion, an average of 4 year
|
The time between the date of first confirmed response to the date of the first documented tumour progression, or death due to any cause, whichever occurs first.
At the time of the analysis, several limitations should be taken into consideration for this retrospective study: DOR is only appraisable if measurable disease and DOR data availability in the medical records (ideally assessed with the RECIST criteria) could be incomplete.
|
Through study completion, an average of 4 year
|
Time to treatment failure
大体时间:Through study completion (from date of start of treatment until the date of treatment failure, assessed up to 48 months)
|
Through study completion (from date of start of treatment until the date of treatment failure, assessed up to 48 months)
|
|
Time to Objective Response
大体时间:Through study completion (from date of start of treatment until the date of the first confirmed response, assessed up to 48 months)
|
The time from start of treatment to the date of the first confirmed response (evaluated for responders only)
|
Through study completion (from date of start of treatment until the date of the first confirmed response, assessed up to 48 months)
|
Time to change treatment
大体时间:Through study completion (from date of start of treatment until the date of change treatment, assessed up to 48 months)
|
Through study completion (from date of start of treatment until the date of change treatment, assessed up to 48 months)
|
|
Time to next treatment
大体时间:Through study completion (from date of start of treatment until the date of start other treatment, assessed up to 48 months)
|
Through study completion (from date of start of treatment until the date of start other treatment, assessed up to 48 months)
|
|
All suspected Grade 3/4/5 adverse reactions
大体时间:Through study completion, an average of 4 year
|
Through study completion, an average of 4 year
|
|
Adverse events of special interest to anti HER2 Mab (AESI)
大体时间:Through study completion, an average of 4 year
|
|
Through study completion, an average of 4 year
|
AEs of scientific interest
大体时间:Through study completion, an average of 4 year
|
|
Through study completion, an average of 4 year
|
合作者和调查者
调查人员
- 首席研究员:Belén Ruiz-Antorán, PhD、Department of Clinical Pharmacology, University Hospital Puerta de Hierro Majadahonda, Madrid, Spain
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.